Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biological targets for precision medicines.
The discovery of CRISPR-Cas9 systems has fuelled a rapid expansion of gene editing adoption with particular interest in the increasingly prevalent area of functional genomic screening.
As these technologies have matured and evolved, so have the applications to which they are deployed. While early efforts were heavily enriched for studies in cancer biology, the advent of more complex phenotypic analyses, coupled to CRISPR-based discovery efforts, have substantially broadened the impact of these tools to provide discovery opportunities in myriad disease areas with greater power for hit ID and fewer off-target effects than other screening tools.
Original article by Dr Steffen Lawo and Dr Carlos le Sage
If you'd like to view the original article then follow the link below:
[ Ссылка ]
You can also download the original article pdf here:
[ Ссылка ]-how-phenotypic-crispr.pdf
For more information on Drug Discovery World, head to:
[ Ссылка ]
